BiotechTube

LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Dec 1, 2009 → Aug 1, 2010

NCT ID
NCT01018810

About LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous

LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous is a phase 2 stage product being developed by Eli Lilly for Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01018810. Target conditions include Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Psoriasis were approved

Approved (20) Terminated (3) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Ilumya Injectable ProductSun PharmaceuticalApproved
✅TildrakizumabSun PharmaceuticalApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01018810Phase 2Terminated

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
PPC-06 400 mg QD + PPC-06 400 mg BID + PPC-06 600 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
XP23829 400 mg QD + XP 23829 800 mg QD + XP23829 400 mg BID + PlaceboDr. Reddy's LaboratoriesPhase 2
32
Ixekizumab + PlaceboEli LillyPhase 2
35
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
21
IxekizumabEli LillyPhase 3
40
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
40
Placebo + BaricitinibEli LillyPhase 2
35
CT-P43 + StelaraCelltrionPhase 3
40
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
AMG 139AstraZenecaPhase 1
29
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 2
35
Tacrolimus CreamAstellas PharmaPhase 3
40
alefaceptAstellas PharmaPhase 3
40
peficitinib + PlaceboAstellas PharmaPhase 2
35
AlefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
43